Nectar Lifesci. (NECLIFE)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Deep discount to book value: price ₹12.09 vs book value ₹56.14, P/B of 0.22 offers potential asset margin of safety.
• Promoter holding at 51.84% indicates meaningful insider ownership and alignment.
• Debt-to-equity of 0.64 is not extreme relative to book value.
• Current price near the lower end of the 52-week range of ₹9.30–₹22.40, reducing speculative premium.
• Small market cap of ₹237 Cr leaves room for operational recovery upside if business revives.

Concerns

• Sales growth is -100% and latest quarter sales are ₹0 Cr, indicating no active core revenue generation.
• ROE at -32.94% and ROCE at -5.36% show severe capital destruction.
• Piotroski F-score of 2/9 signals poor financial health and potential distress.
• Profit growth of -9026.09% and P/E of 0.00 make earnings quality highly questionable; the ₹14 Cr net profit appears non-operating.

AI Analysis

At ₹12.09, this stock looks like a Graham-style statistical bargain on the surface: price-to-book of 0.22 against a book value of ₹56.14. But Buffett always reminds us that the best bargain is a wonderful company at a fair price, not a poor business at any price. Here, the operating engine has stalled. Sales growth is -100% and the latest quarter shows ₹0 Cr of revenue. That is not a pharmaceutical business; it is a shell waiting for a story. The market cap is ₹237 Cr, but with ROE at -32.94% and ROCE at -5.36%, the company is destroying shareholder capital, not compounding it. The Piotroski F-score of 2/9 reinforces the picture of weak financial health. Profit growth of -9026% and a P/E of 0.00 tell me current earnings are meaningless. The reported net profit of ₹14 Cr against zero sales is suspicious—it smells like non-operating income, not a durable franchise. Debt-to-equity of 0.64 is manageable but uncomfortable when the revenue line has vanished. Promoter holding of 51.84% is a positive, but ownership alone is not a moat. This is a deep value asset play, not a quality compounder. The market is pricing a massive discount to book, which may be justified if assets are impaired or the business cannot return to profitability. As Graham would say, price is what you pay, value is what you get. Here, I get no earnings evidence to validate the value. I would need to see restored sales, positive operating cash flow, and credible capital allocation before acting. Patience is essential.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer